153 related articles for article (PubMed ID: 9291802)
1. POMB/ACE chemotherapy for mediastinal germ cell tumours.
Bower M; Brock C; Holden L; Nelstrop A; Makey AR; Rustin GJ; Newlands ES
Eur J Cancer; 1997 May; 33(6):838-42. PubMed ID: 9291802
[TBL] [Abstract][Full Text] [Related]
2. POMB/ACE chemotherapy for mediastinal germ-cell tumours.
Droz JP
Eur J Cancer; 1997 May; 33(6):809-11. PubMed ID: 9291797
[No Abstract] [Full Text] [Related]
3. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
4. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.
Bower M; Newlands ES; Holden L; Rustin GJ; Begent RH
Ann Oncol; 1997 May; 8(5):477-83. PubMed ID: 9233528
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for ovarian germ cell tumours.
Bower M; Fife K; Holden L; Paradinas FJ; Rustin GJ; Newlands ES
Eur J Cancer; 1996 Apr; 32A(4):593-7. PubMed ID: 8695258
[TBL] [Abstract][Full Text] [Related]
6. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
7. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity.
Husband DJ; Green JA
Eur J Cancer; 1992; 28(1):86-91. PubMed ID: 1373636
[TBL] [Abstract][Full Text] [Related]
8. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study.
Gaffan J; Holden L; Newlands ES; Short D; Fuller S; Begent RH; Rustin GJ; Seckl MJ
Br J Cancer; 2003 Nov; 89(10):1849-54. PubMed ID: 14612891
[TBL] [Abstract][Full Text] [Related]
9. Platinum-based chemotherapy of primary extragonadal germ cell tumours: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Aravantinos G; Visvikis A; Bakoyiannis C; Halikia A; Kalofonos C; Kosmidis P; Skarlos D; Fountzilas G
Oncology; 1999 Jul; 57(1):1-9. PubMed ID: 10394118
[TBL] [Abstract][Full Text] [Related]
10. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours.
Ledermann JA; Holden L; Newlands ES; Begent RH; Rustin GJ; Bagshawe KD; Brampton M
Br J Urol; 1994 Aug; 74(2):225-30. PubMed ID: 7522874
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime.
Cullen MH; Harper PG; Woodroffe CM; Kirkbride P; Clarke J
Br J Urol; 1988 Nov; 62(5):454-60. PubMed ID: 2463034
[TBL] [Abstract][Full Text] [Related]
12. Primary chemotherapy for stage 2 testis cancer.
Abratt RP; McAdam GL; Pontin AR; Barnes RD; Ball HS
S Afr J Surg; 1997 Nov; 35(4):203-5; discussion 205-6. PubMed ID: 9540399
[TBL] [Abstract][Full Text] [Related]
13. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.
Francis R; Bower M; Brunström G; Holden L; Newlands ES; Rustin GJ; Seckl MJ
Eur J Cancer; 2000 Oct; 36(15):1925-32. PubMed ID: 11000572
[TBL] [Abstract][Full Text] [Related]
14. [Combination chemotherapy with POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) in advanced non-seminomatous testicular tumor].
Masuda F; Kawahara M; Asano K; Shirakawa H
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1847-50. PubMed ID: 7574821
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.
Hitchins RN; Newlands ES; Smith DB; Begent RH; Rustin GJ; Bagshawe KD
Br J Cancer; 1989 Feb; 59(2):236-42. PubMed ID: 2467682
[TBL] [Abstract][Full Text] [Related]
16. Treatment in germ cell tumours: state of the art.
Tjan-Heijnen VC; Oosterhof GO; de Wit R; De Mulder PH
Eur J Surg Oncol; 1997 Apr; 23(2):110-7. PubMed ID: 9158183
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of two VAB-like regimens (vinblastine + actinomycin-D + bleomycin + cyclophosphamide + cisplatin) in malignant germ cell tumours of the ovary.
Culine S; Lhomme C; Kattan J; Duvillard P; Michel G; Droz JP
Eur J Cancer; 1994; 30A(9):1239-44. PubMed ID: 7528029
[TBL] [Abstract][Full Text] [Related]
18. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.
Gerl A; Clemm C; Schmeller N; Dienemann H; Weiss M; Kriegmair M; Löhrs U; Wilmanns W
Br J Cancer; 1994 Nov; 70(5):960-5. PubMed ID: 7524606
[TBL] [Abstract][Full Text] [Related]
19. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
[TBL] [Abstract][Full Text] [Related]
20. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.
Gerl A; Clemm C; Schmeller N; Hartenstein R; Lamerz R; Wilmanns W
Br J Cancer; 1996 Oct; 74(8):1280-5. PubMed ID: 8883418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
